Amanta Healthcare
Book Building issueMainboardBSE₹126 Cr issue
+6.35%
Listing gain over issue price
Issue size
₹126 Cr
1 lot at cut-off
₹14,994
Lot size
119shares
Open
01 Sep 2025
Close
03 Sep 2025
Allotment
04 Sep 2025
Listing
09 Sep 2025
Listing performance
Issue price
₹126
Listed at
₹134
Listing-day close
₹141.75
Latest price
₹163.07
Close on 23 Oct 2026
Listing gain
+6.35%
Return since issue
+29.42%
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Issue details
- IPO date
- 01 Sep 2025 – 03 Sep 2025
- Listing date
- 09 Sep 2025
- Face value
- ₹1 per share
- Issue price
- ₹126 per share
- Lot size
- 119 shares
- Issue type
- Book Building issue
- Listing at
- BSE
- Total issue size
- ₹126 Cr
- Market cap at offer price
- ₹489 Cr
- Promoter holding
- 85.60% → 63.56% pre-issue → post-issue
- ISIN
- INE084K01015
- Registrar
- MUFG Intime India Pvt.Ltd.
- Lead managers
- Beeline Capital Advisors Pvt.Ltd.
- Registered office
- 8th Floor, Shaligram Corporates, C.J. Marg, Ambli, Gujarat
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Anchor investor · within QIB | 30,00,000 | — | — |
| Market maker | 0 | — | — |
Application size
Minimum 119 shares per lot, in multiples, at ₹126
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 119 | ₹14,994 |
| Retail (max) | 13 | 1,547 | ₹1,94,922 |
| S-HNI (min) | 14 | 1,666 | ₹2,09,916 |
| S-HNI (max) | 66 | 7,854 | ₹9,89,604 |
| B-HNI (min) | 67 | 7,973 | ₹10,04,598 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Anchor investors
Institutional allocation placed a day before the issue opens, carved out of the QIB portion and locked in after listing.
Shares allocated
30,00,000
Anchor portion
₹37.80 Cr
at ₹126 per share
Valuation and performance
Valuation at offer price
₹126 per share
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 3.64 | 2.70 |
| P/E (×) | 34.62 | 46.67 |
| Price to book (×) | 3.77 | — |
| Market cap | — | ₹489 Cr |
Key performance indicators
Latest reported period
- Return on net worth
- 10.89%
- ROCE
- 13.72%
- Debt / equity
- 2.02
- PAT margin
- 3.86%
- EBITDA margin
- 22.11%
- NAV per share
- ₹33.43
- Price to book
- 3.77
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Amanta Healthcare
Amanta Healthcare Limited, originally incorporated as Marck Parenterals (India) Limited in December 1994 and renamed to Amanta Healthcare Limited in June 2014, manufactures large volume parenterals (LVPs) and small volume parenterals (SVPs) in six therapeutic segments using Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technology. The company also manufactures medical devices and offers a wide range of closure systems with container fill-volumes ranging from 2ml to 1000ml. Its formulation and development operations help develop new formulations and modify existing ones for both own brands and product partnering business. The manufacturing facility is located in Hariyala, District Kheda, Gujarat, with cGMP certifications from various regulatory bodies including WHO-compliant certifications.
Company Analysis
from RHPAmanta Healthcare Limited is a pharmaceutical company engaged in developing, manufacturing and marketing sterile liquid products (parenterals, IV fluids, medical devices) using ABFS and ISBM technology across therapeutic segments.
Amanta Healthcare Limited, originally incorporated as Marck Parenterals (India) Limited in December 1994 and renamed to Amanta Healthcare Limited in June 2014, manufactures large volume parenterals (LVPs) and small volume parenterals (SVPs) in six therapeutic segments using Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technology. The company also manufactures medical devices and offers a wide range of closure systems with container fill-volumes ranging from 2ml to 1000ml. Its formulation and development operations help develop new formulations and modify existing ones for both own brands and product partnering business. The manufacturing facility is located in Hariyala, District Kheda, Gujarat, with cGMP certifications from various regulatory bodies including WHO-compliant certifications.
Pharmaceuticals - Parenteral ProductsMedical DevicesSterile Injectable Manufacturing
Objects of the Issue
- Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat ₹7,000.00 lakhs p.26
- Funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up new manufacturing line for SVP at Hariyala, Kheda, Gujarat ₹3,013.11 lakhs p.26
- General corporate purposes p.26
- Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat ₹ 7,000 lakhs p.56
- Funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up new manufacturing line for SVP at Hariyala, Kheda, Gujarat ₹ 3,013.11 lakhs p.56
- General corporate purposes p.59
- Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat ₹7,000.00 lakhs p.140
- Funding capital expenditure requirements towards civil construction work, purchase of equipment, plant and machinery for setting up new manufacturing line for SVP at Hariyala, Kheda, Gujarat ₹3,013.11 lakhs p.140
- General corporate purposes p.140
- Civil construction work and purchase of equipment, plant and machinery for expansion of manufacturing facilities at Hariyala, Kheda, Gujarat ₹ 3,013.11 lakhs p.218
- General corporate purposes p.259
- Expansion of manufacturing capacities p.321
- Not specified in this document section
Issue Structure
- Total Issue
- Up to 1,00,00,000 Equity Shares aggregating up to ₹ [●] lakhs
- Fresh Issue
- Up to 1,00,00,000 Equity Shares aggregating up to ₹ [●] lakhs
- Offer for Sale
- Not Applicable
- Price Band
- ₹ [●] (Floor Price) to ₹ [●] (Cap Price) per Equity Share
- Lot Size
- [●] Equity Shares
- Face Value
- ₹ 10 per Equity Share
Business Model
The company earns revenue through two primary segments: manufacturing and selling sterile liquid pharmaceutical products (LVPs and SVPs) including IV fluids, formulations, diluents, ophthalmic, respiratory care and irrigation solutions; and manufacturing medical devices. Additionally, it generates revenue through product partnering business where it develops and manufactures products for customers. The company sells both domestically and internationally, with 33.06% of revenue from operations coming from exports in FY2025.
Business Segments
Manufacturing of LVPs including IV fluids, formulations, diluents using ABFS and ISBM technology with container fill-volumes ranging from 2ml to 1000ml
Manufacturing of SVPs in therapeutic segments including ophthalmic, respiratory care and irrigation solutions
Manufacturing of medical devices including irrigation solutions, first-aid solutions, eye lubricants and related products
Domestic distribution and sale of injectable pharmaceutical products
Export and sale of injectable pharmaceutical products to international markets
Supply of pharmaceutical products in partnership with foreign and Indian pharmaceutical companies
Manufacturing of sterile low volume prefilled syringes for pharmaceutical applications
Manufacturing of semi-rigid vials and bottles for pharmaceutical packaging
Manufacturing of sterile pre-filled injection systems and related pharmaceutical containers
Manufacturing and marketing of pharmaceutical formulations across multiple therapeutic segments for domestic and international markets
Manufactures sterile liquid formulations of intravenous fluids including dextrose, normal saline, combination of dextrose and normal saline, ringer lactate and electrolytes used for dehydration, heat stroke or loss of fluid due to illness, and supplementary nutrition during critical health conditions. Products available in fill volumes of 100ml, 250ml, 500ml and 1000ml in single and two-port containers.
Manufactures formulation products predominantly catering to injectables, ophthalmic and respiratory therapies. Produces drugs like Ciprofloxacin, Metronidazole, Ofloxacin, Paracetamol, Fluconazole and others in sterile liquid form from API in LVPs and SVPs packaging with fill volumes of 2ml to 100ml in aseptic BFS plastic bottles.
Manufactures diluents mainly offered in pack sizes of 5ml and 10ml, either plain water for injection (WFI) or normal saline WFI. Produces injectables including Lidocaine, Potassium Chloride, Magnesium Sulphate, Calcium Chloride, and Calcium Gluconate.
Manufactures ophthalmic products available in 5ml and 10ml dosage forms used for eyecare, covering eye treatment for infections, glaucoma or inflammation. Products offered in Form Fill Seal (FFS) Pack or Three-Piece conventional pack.
Manufactures respiratory solutions generally in 2.5ml dose form including products like Budesonide, Salbutamol and combinations used through nebulizer for treatment of lungs affected by Asthma or Bronchiectasis.
Manufactures irrigation solutions and medical device products including OTC eye lubricant and wound cleaning solutions available in 5ml, 10ml and 20ml dose forms.
Manufacturing of large volume intravenous formulations including fluid therapy solutions and irrigation solutions, produced through multiple specialised production lines (LVP Line II, L-III)
Manufacturing of small volume injectable formulations and ophthalmic and respiratory nebules products, produced through specialised production lines (SVP Line I, SVP Line II, SteriPort-Debottlenecking)
Manufacturing of sterile ophthalmic ocular lubricant drops and sterile irrigation solutions, with CE Mark certification obtained in 2024
Large Volume Parenterals (LVP) - unit dose containers of more than 100 ml for fluid therapy and related applications
Small Volume Parenterals (SVP) - unit dose containers of less than 100 ml for pharmaceutical formulations
Contract manufacturing services under loan license arrangement where the company manufactures products using customer-provided inputs and specifications
Manufacturing of LVP products (unit dose containers of more than 100 ml) using ABFS and ISBM technology with therapeutic applications including fluid therapy, formulations, diluents, ophthalmic, respiratory care and irrigation solutions. Has 4 manufacturing lines (two conventional single port containers with ABFS technology and two lines for SteriPort products with ISBM technology). As of March 31, 2025, installed capacity of 5.66 crores units annually with actual production of 5.17 crores units (91% utilization).
Manufacturing of SVP products (unit dose containers of less than 100 ml) using ABFS and conventional three-piece container filling lines. Has 3 operational manufacturing lines (two ABFS lines and one conventional three-piece container filling line). As of March 31, 2025, installed capacity of 20.91 crores units annually with actual production of 20.64 crores units (99% utilization).
Manufacturing of SteriPort products using Injection Stretch Blow Moulding (ISBM) technology with two dedicated manufacturing lines. As of March 31, 2025, installed capacity of 6.62 crores units annually with actual production of 6.02 crores units (91% utilization).
Manufacturing of medical device products including irrigation solutions, first-aid solutions, and eye lubricants. Company has DNV certificate for exports of medical device products and cGMP capabilities.
Undertakes commercial large-scale manufacturing of generic products for pharmaceutical companies under loan license agreements and other product partnering arrangements. Provides formulation and development services for customers.
Domestic sales of branded pharmaceutical products through a network of over 320 distributors and stockists. Manufactures diverse generic product portfolio of over 45 products marketed under own brands.
International sales business covering advanced market countries and emerging market countries. Has portfolio of 47 products registered across 113 international jurisdictions. During FY2025, exported branded products to 21 countries including Africa, Latin America, UK and Rest of world.
SWOT Analysis
Strengths
- • Diversified product portfolio with new launches across domestic and export markets(p.51)
- • Consistent quality control investment and compliance with testing standards(p.51)
- • Improved profitability trajectory with recovery from FY2023 losses(p.52)
- • Registered trademark for core brand 'SteriPort' providing brand protection(p.61)
- • Strong capacity utilization across production lines(p.142)
- • Significant installed production capacity base(p.142)
- • Existing freehold land with substantial constructable area for expansion(p.142)
- • Consolidated promoter holding with stability(p.112)
- • Well-established manufacturer with diverse product portfolio and market reach(p.264)
- • Large manufacturing capabilities enabling scale(p.264)
- • Wide domestic and international marketing network(p.264)
- • Experienced management team with large, diverse, and skilled workforce(p.264)
- • Strong EBITDA margins indicating operational efficiency(p.267)
- • Well-established manufacturer with diverse product portfolio across six therapeutic segments(p.320)
- • Large manufacturing capabilities with high capacity utilization and multiple production lines(p.320)
- • WHO-GMP certified manufacturing facility with international quality accreditations(p.328)
- • Wide domestic and international marketing network with 320+ distributors and products registered in 120 international jurisdictions(p.320)
- • Experienced management team with promoter having 30 years of industry experience(p.321)
- • Strong financial performance with improving profitability metrics(p.319)
- • Favorable demographic tailwinds with rising healthcare spending and chronic disease prevalence in India(p.287)
- • Growing IV fluids market with strong projected growth rates(p.294)
- • WHO-GMP certification and multiple ISO accreditations demonstrating manufacturing quality(p.345)
- • Strong regulatory track record with no warning letters or approvals withdrawn(p.346)
- • Sustained contract manufacturing business with cost-plus pricing insulated from market volatility(p.345)
- • Direct customer relationships enabling understanding of technical needs and future requirements(p.345)
- • Diversified production lines for multiple product types (SVP and LVP)(p.359)
- • Stable workforce with no material labor disputes(p.347)
- • Robust quality control infrastructure with 123 QC/QA employees(p.345)
- • Senior management engagement in sales and customer relationship building(p.345)
- • Advanced manufacturing technologies deployed across facilities(p.406)
- • Diversified product portfolio across therapeutic segments(p.406)
- • Established domestic and international market presence(p.406)
- • Profitable operations with improving net profit margins(p.459)
- • Strong return on equity and capital employed(p.459)
- • Improving working capital efficiency(p.459)
- • Diversified product portfolio across six therapeutic segments with sterile liquid manufacturing capabilities(p.467)
- • Advanced manufacturing technology with ABFS and ISBM capabilities and GMP certifications(p.467)
- • Established international presence with products registered in 19 countries and exports to 21 countries(p.468)
- • Strong capacity utilization with 96% overall capacity utilization in FY2025(p.469)
- • Experienced management team with 20+ years of industry experience(p.468)
- • Improved profitability with PAT increasing 189% to ₹1,050.07 lakhs in FY2025(p.477)
Weaknesses
- • Single manufacturing facility creates concentration risk(p.34)
- • High finance costs consuming significant portion of EBITDA(p.38)
- • High debt to equity ratio limiting financial flexibility(p.50)
- • Manufacturing license previously suspended(p.50)
- • Material litigation involving promoter and company(p.36)
- • Significant customer concentration risk(p.48)
- • High employee attrition rate despite recent improvement, creating workforce stability risk(p.54)
- • Minimal R&D capacity with only 4 employees dedicated to formulation and development(p.51)
- • Significant debt burden requiring settlement and restructuring with lenders(p.56)
- • Promoter personal guarantee exposure on substantial borrowings creating financial vulnerability(p.57)
- • Historical losses and fluctuating profitability with no assurance of future improvement(p.56)
- • Missing secretarial records creating potential regulatory and compliance risks(p.62)
- • Outstanding trade payables to multiple creditors including micro/small enterprises(p.56)
- • Regulatory compliance failures documented by FDA inspections with unresolved facility acceptability issues(p.52)
- • Significant pledged promoter shareholding creating financial risk(p.124)
- • Lack of bank/financial institution appraisal of capital expansion plans(p.141)
- • High dependency on capital expenditure for growth with execution risk(p.140)
- • High customer concentration risk with top customer contributing 4% of revenue(p.268)
- • High supplier concentration with top 1 supplier contributing 23.94% of purchases(p.268)
- • Significant leverage with Debt Equity Ratio of 2.02(p.267)
- • Declining revenue from operations with 2.01% negative growth(p.267)
- • High debt-to-equity ratio indicating significant financial leverage(p.319)
- • Dependence on limited suppliers for critical raw materials LDPE and PP granules(p.342)
- • Concentrated sourcing with top supplier accounting for nearly 24% of materials(p.341)
- • Declining revenue from operations in FY2025(p.319)
- • Relatively low PAT margin despite improvements(p.319)
- • High dependence on domestic market with 67.32% of revenue from India(p.344)
- • Significant exposure to single dominant export market with Sudan accounting for 3.92% of revenue(p.344)
- • Historical default on debt obligations in 2021(p.360)
- • High power and fuel costs representing 8.50% of adjusted expenses(p.346)
- • Partial insurance coverage with only 73% of total assets insured(p.347)
- • Declining domestic revenue from ₹19,816.89 lakhs in FY2024 to ₹18,493.54 lakhs in FY2025(p.344)
- • High leverage with significant debt obligations(p.444)
- • Elevated debt-to-equity ratio despite recent improvement(p.459)
- • Exposure to foreign exchange volatility with unhedged positions(p.446)
- • Deteriorating interest coverage due to high debt servicing costs(p.459)
- • Low absolute cash position relative to operating needs(p.417)
- • Declining inventory turnover indicating slower sales realization(p.459)
- • Multiple contingent liabilities from regulatory disputes(p.431)
- • Financial covenant breaches requiring lender waivers(p.420)
- • Significant dependence on few customers with top 5 customers accounting for 16.84% of revenue(p.469)
- • High financial leverage with debt-to-equity ratio of 2.02 and significant finance costs(p.468)
- • Single manufacturing facility location creates operational concentration risk(p.469)
- • Heavy dependence on raw material suppliers with largest supplier accounting for 23.94% of materials sourced(p.470)
- • Revenue decline of 2.01% in FY2025 despite improved profitability(p.476)
- • Low cash reserves with only ₹22.06 lakhs of cash and cash equivalents as of March 31, 2025(p.480)
- • Ongoing criminal proceedings related to product quality issues(p.490)
Opportunities
- • Expanding IV fluids market with strong growth trajectory(p.25)
- • Growing healthcare budget supporting industry expansion(p.25)
- • New manufacturing capacity for SteriPort and SVP products(p.26)
- • International market expansion into new geographies(p.47)
- • Planned capacity expansion in high-margin intravenous formulations manufacturing(p.56)
- • Expansion of product portfolio across both domestic and export markets(p.51)
- • Growing pharmaceutical industry demand driven by healthcare reforms and accessibility focus(p.55)
- • Planned capacity expansion with clear investment strategy(p.143)
- • Significant incremental capacity additions targeted for FY2026-27(p.142)
- • Market visibility and brand enhancement through public listing(p.140)
- • Dual production line expansion enabling diversified product offerings(p.140)
- • Capacity expansion for manufacturing of SVP with production commencing January 2027(p.218)
- • Proposed substantial capital investment of ₹3,013.11 lakhs for new manufacturing line(p.218)
- • Enhanced automated processes and facility improvements through capex(p.218)
- • Expansion of manufacturing capacities in high-margin LVP and SVP segments(p.321)
- • Growth in domestic branded generics business through expanded distribution network(p.321)
- • Expansion into regulated markets and new geographies(p.343)
- • Growing demand for complex generics and specialty injectables(p.294)
- • Increasing health insurance penetration and government healthcare schemes like Ayushman Bharat(p.294)
- • Rising prevalence of chronic diseases requiring injectable therapies(p.294)
- • Expanding contract manufacturing and product partnering opportunities(p.321)
- • Preference for FFS packs enabling customer registrations at the Company's site with pack format changes(p.345)
- • Expansion of contract manufacturing for specialized ophthalmic and respiratory nebules products(p.345)
- • Opportunity to provide SWFI (Sterile Water for Infusion) manufacturing for pharma companies(p.345)
- • Potential for additional work extraction from existing customers through site-based project management(p.345)
- • CE Mark certification for Eye Wash Solutions enabling product diversification(p.359)
- • Approval to manufacture and market new domestic product (Linezolid I.V. injection)(p.359)
- • Capacity expansion through approved facilities and capital commitments(p.431)
- • Growth in parenteral drug segment driven by healthcare expansion(p.406)
- • International market penetration with growing export revenues(p.453)
- • Contract manufacturing services expansion under loan license arrangements(p.425)
- • Refinancing at favorable rates with new financial institution borrowings(p.421)
- • Unutilized borrowing facilities available for future growth(p.421)
- • Expansion of international markets with portfolio of 47 products across 113 international jurisdictions(p.468)
- • Growing product partnering business with manufacturing for various pharmaceutical companies(p.468)
- • Strong domestic market presence through network of over 320 distributors and stockists(p.468)
- • Dedicated R&D capabilities with formulation and development laboratory for new product development(p.467)
Threats
- • Facility disruption from regional political/natural disasters(p.34)
- • Volatile raw material prices linked to crude oil(p.30)
- • Intense competition in pharmaceutical industry(p.44)
- • Foreign exchange fluctuation risk on exports and imports(p.49)
- • Regulatory restrictions and import duties on plastic granules(p.43)
- • Extensive pharmaceutical regulatory compliance requirements(p.46)
- • Labour-intensive operations susceptible to strikes and wage demands(p.38)
- • Regulatory price controls on pharmaceutical products limiting revenue potential(p.55)
- • Product liability exposure from intravenous formulations injected directly into bloodstream(p.55)
- • Global economic slowdown and currency fluctuations affecting export markets(p.66)
- • Intense competition from established pharmaceutical companies with greater resources(p.54)
- • Indian economic slowdown and inflation eroding margins(p.66)
- • Increasing employee compensation costs eroding competitive advantage(p.67)
- • Natural disasters and supply chain disruptions affecting manufacturing operations(p.67)
- • Foreign investment restrictions under Indian law limiting capital access(p.73)
- • Project cost and deployment subject to market condition volatility(p.141)
- • Risk of funding requirement shortfall affecting expansion timeline(p.141)
- • Capital intensity and execution risk of ₹3,013.11 lakhs capex project(p.218)
- • Delayed production commencement from new facility impacting returns(p.218)
- • Dependence on specific vendors with no guarantee of supply continuity(p.218)
- • Fluctuation risk in machinery costs prior to final placement of orders(p.218)
- • Volatile pricing of crude oil-linked raw materials LDPE and PP granules(p.342)
- • Government drug price control regulations including DPCO(p.292)
- • Pricing pressure in US markets and wholesale consolidation(p.292)
- • Highly fragmented and competitive domestic formulation industry(p.292)
- • Dependence on China for ~70% of API intermediaries and potential supply disruptions(p.292)
- • US FDA compliance and data integrity challenges(p.292)
- • Global economic slowdown and trade tensions impacting exports(p.302)
- • Dependence on imports for key raw materials subject to global supply chain disruptions(p.345)
- • Regulatory changes to pharmaceutical pricing and quality standards(p.346)
- • Intense competition from local, multinational and emerging market competitors(p.347)
- • Exposure to pharmaceutical industry cyclicality and market volatility(p.347)
- • Currency fluctuation risks from export operations (32.68% of revenue)(p.344)
- • Risk of product liability if manufactured products do not comply with regulatory standards(p.347)
- • Environmental and hazardous waste management compliance costs and penalties(p.353)
- • Volatility in international market demand particularly for African and Middle Eastern markets(p.344)
- • Regulatory compliance risks and tax disputes(p.431)
- • Price regulation exposure under Drug Price Control Order(p.431)
- • Interest rate risk on floating-rate borrowings(p.445)
- • Significant exposure to pharmaceutical industry cyclicality and competition(p.425)
- • Customer concentration dependency risks(p.453)
- • Raw material and input price volatility(p.427)
- • Lease obligation commitments affecting cash flow flexibility(p.432)
- • Extensive pharmaceutical market regulation and price controls affecting product pricing(p.471)
- • Volatile raw material prices linked to crude oil prices affecting LDPE and PP granules(p.470)
- • Intense competition from regional and multi-national pharmaceutical companies(p.471)
- • Risk of business disruption due to single manufacturing facility location(p.469)
- • Lack of long-term supply agreements with raw material suppliers creating procurement risk(p.470)
- • Outstanding indirect tax proceedings with aggregate amount of ₹1,465.22 lakhs(p.491)
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Bhavesh Patel | Promoter | 21.68% | — |
| Vishal Patel | Promoter | 13.55% | — |
| Jayshreeben Patel | Promoter | 3.46% | — |
| Jitendrakumar Patel | Promoter | 12.09% | — |
| Milcent Appliances Private Limited | Promoter | 10.75% | — |
| Bhavesh Patel | Promoter | 21.59% | — |
| Bhavesh Patel | Promoter | 21.68% | — |
| Vishal Patel | Promoter | 13.55% | — |
| Jitendrakumar Patel | Promoter | 12.09% | — |
| Praful Patel | Promoter Group | 7.92% | — |
| Milcent Appliances Private Limited | Promoter | 10.75% | — |
| Jayshreeben Patel | Promoter | 3.46% | — |
| Pravinchandra Mehta | Promoter Group | 6.88% | — |
| Niranjanbhai Patel | Promoter Group | 5.22% | — |
| Kirit Desai | Promoter Group | 3.93% | — |
| Bhavesh Patel | Promoter | — | — |
| Bhavesh Patel | Promoter | 21.68% | — |
| Vishal Patel | Promoter | 13.55% | — |
| Jayshreeben Patel | Promoter | 3.46% | — |
| Jitendrakumar Patel | Promoter | 12.09% | — |
| Milcent Appliances Private Limited | Promoter | 10.75% | — |
| Mr. Bhavesh G. Patel | Promoter | 14.71% | 21.64% |
| Mr. Jitendra J. Patel | Promoter | 11.42% | 12.09% |
| Mr. Vishal A. Patel | Promoter | 12.24% | 13.55% |
| Milcent Appliances Private Limited | Promoter | 11.55% | 10.75% |
| Jayshreeben R. Patel | Promoter | 3.72% | 3.46% |
| Bhavesh Patel | Promoter | — | — |
Leadership
Bhavesh Patel · Chairman and Managing Director
Paras Mehta · Chief Financial Officer
Nikhita Dinodia · Company Secretary and Compliance Officer
Auto-extracted from the company's RHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official RHP before relying on it.
Amanta Healthcare IPO FAQs
What is the lot size of Amanta Healthcare IPO?
The minimum lot size of Amanta Healthcare IPO is 119 shares. One lot costs ₹14,994 at the cut-off price.
When does Amanta Healthcare IPO open and close?
Amanta Healthcare IPO opened for subscription on 01 Sep 2025 and closed on 03 Sep 2025.
What is the listing date of Amanta Healthcare IPO?
Amanta Healthcare IPO listed on 09 Sep 2025.